Fairvalue-Calculator Fairvalue-Calculator
EN DE

Darwin AG (7V0) Fair Value & Analysis

Healthcare · DE · Market cap €73.8M

Price€7.55
Fair Value€1.61
Upside-78.7%
Quality95/100
Evidence: Medium Range €1.13 – €2.09

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Darwin AG (7V0) currently trades at €7.55, while our model-based Fair Value estimate is €1.61 — implying the stock looks roughly 78.7% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).

About the company

Darwin AG operates in the healthcare industry. The company offers dietary supplements and cosmetics products. It also provides consulting and support services. The company was incorporated in 2021 and is based in Munich, Germany.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -88% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -27% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +9% Alnylam Pharmaceuticals, Inc (ALNY) -62%

Frequently asked questions

Is Darwin AG (7V0) undervalued?
As of Jun 24, 2026, our model estimates a fair value of €1.61 versus a price of €7.55 — about −79% (overvalued). Model-based estimate, not financial advice.
What is the fair value of 7V0?
Our 21-model fair value for Darwin AG is €1.61 (as of Jun 24, 2026), built from audited fundamentals. The current price is €7.55.
What is the quality score of 7V0?
Darwin AG has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.